HyGro, if the patients in the DCVax-L trial were cherry picked, why was the mOS of the 131 unmethylated patients in the treatment arm (about 40% of the patients in the trial), only 0.3 months longer than the mOS of the ECAs? This documents that there was no cherry picking in this trial
Furthermore, if DCVax-L is ineffective, it would not matter if you administered patients one dose or multiple doses and by the way, the original protocol did call for multiple doses of DCVax-L and the investigators followed that protocol. So why would anyone object to the protocol and decide that the patients should only receive DCVax-L once?
Finally, the UCLA combo trial while, incomplete, demonstrates that about 60% of
the patients receiving the combo treatment, have already survived 800(+) days past their progression. Whatever happens to those survivors in the next months or years, that trial is already a success because it strongly suggests that without the DCVax-L component of the combo treatment, such spectacular survival results would not be possible. This is obvious because other treatments (i.e. keytruda, poly ICLC etc.) have so far not obtained such long survival results.
Market Data 
Markets 
